BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, Bloom RD, Nazarian SM, Sawinski D, Porrett P, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Farooqi M, Gentile C, Smith J, Reese PP. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. N Engl J Med. 2017;376:2394-2395. [PMID: 28459186 DOI: 10.1056/nejmc1705221] [Cited by in Crossref: 223] [Cited by in F6Publishing: 67] [Article Influence: 44.6] [Reference Citation Analysis]
Number Citing Articles
1 Concepcion BP, Binari LA, Schaefer H, Rega S, Feurer I, Shawar S, Naik R, Hickman L, Walker J, Kapp M, Birdwell KA, Langone A, Helderman JH, Ann Sarrell B, Kochar G, Dubray B, Smith K, O'Dell H, DeMers A, Shelton P, Perri R, Shaffer D, Forbes RC. Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting. Transplant Direct 2021;7:e761. [PMID: 34514116 DOI: 10.1097/TXD.0000000000001217] [Reference Citation Analysis]
2 El Helou G, Jay C, Nunez M. Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts. Transplantation Reviews 2022;36:100677. [DOI: 10.1016/j.trre.2021.100677] [Reference Citation Analysis]
3 Chan S, Isbel NM, Hawley CM, Campbell SB, Campbell KL, Morrison M, Francis RS, Playford EG, Johnson DW. Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. Medicina (Kaunas) 2019;55:E672. [PMID: 31590269 DOI: 10.3390/medicina55100672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Sageshima J, Troppmann C, McVicar JP, Santhanakrishnan C, de Mattos AM, Perez RV. Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients. Transplantation 2018;102:1179-87. [PMID: 29953423 DOI: 10.1097/TP.0000000000002096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Van Pilsum Rasmussen SE, Seaman S, Brown D, Desai N, Sulkowski M, Segev DL, Durand CM, Sugarman J. Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empir Bioeth 2020;11:40-52. [PMID: 31618112 DOI: 10.1080/23294515.2019.1670277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 González-Corvillo C, Beneyto I, Sánchez-Fructuoso A, Perelló M, Alonso A, Mazuecos A, Jiménez C, Zárraga S, Paul J, Lauzurica R, Hernández D, Guirado L, Franco A, Ruiz JC, Llorente S, Crespo M, Rodríguez-Benot A, de Gracia Guindo MDC, Díaz-Corte C, Gentil MÁ. Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study. Transplant Direct 2019;5:e510. [PMID: 32095505 DOI: 10.1097/TXD.0000000000000954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Chang SH, Merzkani M, Lentine KL, Wang M, Axelrod DA, Anwar S, Schnitzler MA, Wellen J, Chapman WC, Alhamad T. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. Clin J Am Soc Nephrol 2021;16:251-61. [PMID: 33451990 DOI: 10.2215/CJN.10960720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol 2020;31:2678-87. [PMID: 32843477 DOI: 10.1681/ASN.2020050686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
9 Shelton BA, Sawinski D, Linas BP, Reese PP, Mustian M, Hungerpiller M, Reed RD, MacLennan PA, Locke JE. Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation. Am J Transplant 2018;18:2483-95. [PMID: 30058218 DOI: 10.1111/ajt.15040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Vinson AJ, Chauhan P, Daley C, De Silva H, Tennankore KK, Bonnar P, West KA. Successful Use of Kidneys from a Deceased Donor with Active Herpes Zoster Infection. Case Rep Transplant 2021;2021:7719041. [PMID: 34434591 DOI: 10.1155/2021/7719041] [Reference Citation Analysis]
11 Logan C, Yumul I, Cepeda J, Pretorius V, Adler E, Aslam S, Martin NK. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant 2021;21:657-68. [PMID: 32777173 DOI: 10.1111/ajt.16245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ruck JM, Segev DL. Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV. Curr Opin Nephrol Hypertens 2018;27:445-53. [PMID: 30169460 DOI: 10.1097/MNH.0000000000000456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
13 Durand CM, Bowring MG, Thomas AG, Kucirka LM, Massie AB, Cameron A, Desai NM, Sulkowski M, Segev DL. The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Ann Intern Med 2018;168:702-11. [PMID: 29710288 DOI: 10.7326/M17-2451] [Cited by in Crossref: 108] [Cited by in F6Publishing: 37] [Article Influence: 27.0] [Reference Citation Analysis]
14 Aguilar A. Transplantation: Anti-viral therapy enables transplantation of HCV+ kidneys. Nat Rev Nephrol 2017;13:382. [PMID: 28502985 DOI: 10.1038/nrneph.2017.68] [Reference Citation Analysis]
15 Liyanage L, Muzaale AD, Henderson ML, Durand CM. Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence. Curr Transplant Rep 2019;6:167-76. [PMID: 32855901 DOI: 10.1007/s40472-019-00242-5] [Reference Citation Analysis]
16 Tronina O, Durlik M, Orłowska I, Lorenc B, Łapiński TW, Garlicki A, Dybowska D, Zarębska-Michaluk D, Tudrujek-Zdunek M, Citko J, Janczewska E, Kaczmarczyk M, Jaroszewicz J, Krygier R, Klapaczyński J, Dobracka B, Białkowska-Warzecha J, Piekarska A, Simon K, Halota W, Pawłowska M, Tomasiewicz K, Flisiak R. Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. Ann Gastroenterol 2021;34:438-46. [PMID: 33948071 DOI: 10.20524/aog.2021.0595] [Reference Citation Analysis]
17 Durand CM, Barnaba B, Yu S, Brown DM, Chattergoon MA, Bair N, Naqvi FF, Sulkowski M, Segev DL, Desai NM. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study. Ann Intern Med 2021;174:137-8. [PMID: 32894697 DOI: 10.7326/M20-1468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
19 Goetsch MR, Tamhane A, Overton ET, Towns GC, Franco RA. Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality. Pathog Immun 2020;5:275-90. [PMID: 33089036 DOI: 10.20411/pai.v5i1.369] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Yuan Q, Cui H, Leya GA, Hong S, Roth EM, Sise ME, Bethea ED, Yeh H, Williams WW, Elias N. Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. Transpl Int 2021;34:2562-9. [PMID: 34726801 DOI: 10.1111/tri.14152] [Reference Citation Analysis]
21 Porrett PM, Orandi BJ, Kumar V, Houp J, Anderson D, Cozette Killian A, Hauptfeld-Dolejsek V, Martin DE, Macedon S, Budd N, Stegner KL, Dandro A, Kokkinaki M, Kuravi KV, Reed RD, Fatima H, Killian JT Jr, Baker G, Perry J, Wright ED, Cheung MD, Erman EN, Kraebber K, Gamblin T, Guy L, George JF, Ayares D, Locke JE. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am J Transplant 2022. [PMID: 35049121 DOI: 10.1111/ajt.16930] [Reference Citation Analysis]
22 Keller J, Marklin G, Okoye O, Desai R, Sura T, Jain A, Varma C, Nazzal M. Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool. J Transplant 2021;2021:6612453. [PMID: 33564467 DOI: 10.1155/2021/6612453] [Reference Citation Analysis]
23 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
24 Calogero A, Sagnelli E, Creta M, Angeletti S, Peluso G, Incollingo P, Candida M, Minieri G, Carlomagno N, Dodaro CA, Ciccozzi M, Sagnelli C. Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients. Biomed Res Int. 2019;2019:4674560. [PMID: 31179323 DOI: 10.1155/2019/4674560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
25 Joglekar K, Eason JD, Molnar MZ. Do we really need more evidence to use hepatitis C positive donor kidney more liberally? Clin Kidney J 2017;10:560-3. [PMID: 28835817 DOI: 10.1093/ckj/sfx067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ibrahim M, Kilic A. Commentary: Heart transplantation using hepatitis C-positive donors: What are we waiting for? J Thorac Cardiovasc Surg 2020:S0022-5223(20)32652-0. [PMID: 33046230 DOI: 10.1016/j.jtcvs.2020.09.055] [Reference Citation Analysis]
27 Holscher CM, Durand CM, Desai NM. Expanding the Use of Organs From Hepatitis C-Viremic Donors: The Evidence Continues to Build. Transplantation 2018;102:546-7. [PMID: 29176392 DOI: 10.1097/TP.0000000000002032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Farmakiotis D, Weiss Z, Brotherton AL, Morrissey P, Gohh R, Vieira K, Taylor LE, Garland JM. Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era. Case Reports Hepatol 2020;2020:7679147. [PMID: 32082657 DOI: 10.1155/2020/7679147] [Reference Citation Analysis]
29 Gill JS, Formica RN, Levitsky J. Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. J Am Soc Nephrol 2019;30:1778-80. [PMID: 31570540 DOI: 10.1681/ASN.2019070726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Cuvelier S, Van Caeseele P, Kadatz M, Peterson K, Sun S, Dodd N, Werestiuk K, Koulack J, Nickerson P, Ho J. Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report. Can J Kidney Health Dis 2021;8:20543581211033496. [PMID: 34367648 DOI: 10.1177/20543581211033496] [Reference Citation Analysis]
31 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Sharma TS, Michaels MG, Danziger-Isakov L, Herold BC. Clinical Vignettes: Donor-Derived Infections. J Pediatric Infect Dis Soc 2018;7:S67-71. [PMID: 30590624 DOI: 10.1093/jpids/piy129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Werbel WA, Durand CM. Pro: Use of Hepatitis C Virus-Positive Donors Should Be Considered Standard of Care. Clin Liver Dis (Hoboken) 2018;12:100-4. [PMID: 30988922 DOI: 10.1002/cld.743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
34 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
35 Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation. F1000Res. 2019;8. [PMID: 30828430 DOI: 10.12688/f1000research.16627.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
36 La Manna G. HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs). J Nephrol 2018;31:185-7. [PMID: 29411309 DOI: 10.1007/s40620-018-0476-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
37 Solli P, Dolci G, Ranieri VM. The new frontier of hepatitis C virus (HCV)-mismatched heart and lung transplantation. Ann Transl Med 2019;7:S279. [PMID: 32015998 DOI: 10.21037/atm.2019.11.123] [Reference Citation Analysis]
38 White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct 2019;5:e416. [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
39 Callaghan CJ, Marks SD. Utilisation of kidneys from deceased donors at increased risk of infectious disease transmission: a step in the right direction. Pediatr Nephrol 2020;35:177-9. [PMID: 31667621 DOI: 10.1007/s00467-019-04380-x] [Reference Citation Analysis]
40 Shetty A, Buch A, Saab S. Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. Dig Dis Sci 2019;64:1110-8. [PMID: 30560331 DOI: 10.1007/s10620-018-5404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
41 Mitchell RA, Hussaini T, Yau AH, Krajden M, Wright AJ, Scudamore CH, Marquez Azalgara V, Erb SR, Yoshida EM. Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission. Transplant Direct 2018;4:e347. [PMID: 29707618 DOI: 10.1097/TXD.0000000000000763] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Roth D, Ladino M. Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource. J Am Soc Nephrol 2017;28:3139-41. [PMID: 28874402 DOI: 10.1681/ASN.2017060673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
43 Jones JM, Kracalik I, Levi ME, Bowman JS 3rd, Berger JJ, Bixler D, Buchacz K, Moorman A, Brooks JT, Basavaraju SV. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020;69:1-16. [PMID: 32584804 DOI: 10.15585/mmwr.rr6904a1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
44 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019;6:20. [PMID: 30800660 DOI: 10.3389/fmed.2019.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
45 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
46 Sise ME, Strohbehn IA, Chute DF, Gustafson J, Van Deerlin VM, Smith JR, Gentile C, Wojciechowski D, Williams WW, Elias N, Chung RT. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep 2020;5:459-67. [PMID: 32280841 DOI: 10.1016/j.ekir.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
47 Ting PS, Hamilton JP, Gurakar A, Urrunaga NH, Ma M, Glorioso J, King E, Toman LP, Wesson R, Garonzik-Wang J, Ottmann S, Philosophe B, Sulkowski M, Cameron AM, Durand CM, Chen PH. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis 2019;21:e13194. [PMID: 31609520 DOI: 10.1111/tid.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
48 Murakami N, Ding Y, Cohen DJ, Chandraker AK, Rennke HG. Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir). Transpl Infect Dis 2018;20:e12959. [PMID: 29968947 DOI: 10.1111/tid.12959] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Anesi JA, Blumberg EA, Han JH, Lee DH, Clauss H, Climaco A, Hasz R, Molnar E, Alimenti D, West S, Bilker WB, Tolomeo P, Lautenbach E; CDC Prevention Epicenters Program. Risk factors for multidrug-resistant organisms among deceased organ donors. Am J Transplant 2019;19:2468-78. [PMID: 31162785 DOI: 10.1111/ajt.15488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
50 Feld JJ, Ward JW. Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. Hepatol Commun 2021;5:911-22. [PMID: 34141979 DOI: 10.1002/hep4.1731] [Reference Citation Analysis]
51 Timsit JF, Sonneville R, Kalil AC, Bassetti M, Ferrer R, Jaber S, Lanternier F, Luyt CE, Machado F, Mikulska M, Papazian L, Pène F, Poulakou G, Viscoli C, Wolff M, Zafrani L, Van Delden C. Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients. Intensive Care Med 2019;45:573-91. [PMID: 30911807 DOI: 10.1007/s00134-019-05597-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
52 Moss S, Boucher HW. What's Hot in Clinical Infectious Diseases? 2019 IDWeek Summary. Open Forum Infect Dis 2020;7:ofaa104. [PMID: 32352020 DOI: 10.1093/ofid/ofaa104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Yazawa M, Fülöp T, Cseprekal O, Talwar M, Balaraman V, Bhalla A, Azhar A, Kovesdy CP, Eason JD, Molnar MZ. The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients. Ren Fail 2020;42:1083-92. [PMID: 33100098 DOI: 10.1080/0886022X.2020.1835675] [Reference Citation Analysis]
54 Azhar A, Binari LA, Joglekar K, Tsujita M, Talwar M, Balaraman V, Bhalla A, Eason JD, Hall IE, Rofaiel G, Forbes RC, Shaffer D, Concepcion BP, Molnar MZ. Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys. Clin Transplant 2021;:e14485. [PMID: 34523744 DOI: 10.1111/ctr.14485] [Reference Citation Analysis]
55 Siddiqi HK, Schlendorf KH. Hepatitis C Positive Organ Donation in Heart Transplantation. Curr Transplant Rep 2021;:1-9. [PMID: 34786324 DOI: 10.1007/s40472-021-00350-1] [Reference Citation Analysis]
56 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
57 Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med 2018;168:533-40. [PMID: 29507971 DOI: 10.7326/M17-2871] [Cited by in Crossref: 164] [Cited by in F6Publishing: 61] [Article Influence: 41.0] [Reference Citation Analysis]
58 Rawashdeh B, Hulse J, Agarwal A. Transplant of a Kidney from a Hepatitis C Viremic Donor to a Naïve Recipient without Viral Transmission: A Case Report. Am J Case Rep 2021;22:e927532. [PMID: 33953151 DOI: 10.12659/AJCR.927532] [Reference Citation Analysis]
59 Karpel HC, Ali NM, Lawson N, Tatapudi VS, Friedlander R, Philogene MC, Montgomery RA, Lonze BE. Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor. Case Rep Transplant 2020;2020:3591274. [PMID: 32231847 DOI: 10.1155/2020/3591274] [Reference Citation Analysis]
60 Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018;67:2085-2095. [PMID: 29222916 DOI: 10.1002/hep.29723] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
61 Madhusoodanan J. Inner Workings: Advances in infectious disease treatment promise to expand the pool of donor organs. Proc Natl Acad Sci U S A 2021;118:e2100577118. [PMID: 33597292 DOI: 10.1073/pnas.2100577118] [Reference Citation Analysis]
62 Shaffer AA, Thomas AG, Bowring MG, Van Pilsum Rasmussen SE, Cash A, Kucirka LM, Alqahtani SA, Gurakar A, Sulkowski MS, Cameron AM, Segev DL, Durand CM. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 2018;20:e12982. [PMID: 30144258 DOI: 10.1111/tid.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
63 Goel A, Bhadauria DS, Aggarwal R. Hepatitis C virus infection and chronic renal disease: A review. Indian J Gastroenterol 2018;37:492-503. [PMID: 30560540 DOI: 10.1007/s12664-018-0920-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
64 Fabrizi F, Messa P. Treatment Choices for Hepatitis C in Patients with Kidney Disease. Clin J Am Soc Nephrol 2018;13:793-5. [PMID: 29523677 DOI: 10.2215/CJN.12621117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Bowring MG, Kucirka LM, Massie AB, Ishaque T, Bae S, Shaffer AA, Garonzik Wang J, Sulkowski M, Desai N, Segev DL, Durand CM. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. Transplantation 2018;102:2088-95. [PMID: 29912046 DOI: 10.1097/TP.0000000000002323] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
66 Duerr M, Liefeldt L, Friedersdorff F, Choi M, Öllinger R, Hofmann J, Budde K, Schrezenmeier E, Halleck F. Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. J Clin Med 2020;10:E89. [PMID: 33383877 DOI: 10.3390/jcm10010089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Edwards GC, Shipe ME, Smith L, Gamble C, Shaffer D, Concepcion BP, Forbes R. Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation. BMC Nephrol 2020;21:473. [PMID: 33172408 DOI: 10.1186/s12882-020-02114-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lentine KL, Peipert JD, Alhamad T, Caliskan Y, Concepcion BP, Forbes R, Schnitzler M, Chang SH, Cooper M, Bloom RD, Mannon RB, Axelrod DA. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360 2020;1:1291-9. [PMID: 33251523 DOI: 10.34067/KID.0004592020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
69 Skladany L, Janceková D, Svac J. Hepatitis C virus antibodies in outpatients with chronic kidney disease. Clin Exp Hepatol 2018;4:267-70. [PMID: 30603675 DOI: 10.5114/ceh.2018.80129] [Reference Citation Analysis]
70 Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Fanikos J, Harrington DP, Camp PC, Baden LR;  DONATE HCV Trial Team. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med. 2019;380:1606-1617. [PMID: 30946553 DOI: 10.1056/nejmoa1812406] [Cited by in Crossref: 146] [Cited by in F6Publishing: 34] [Article Influence: 48.7] [Reference Citation Analysis]
71 Sise ME, Wojciechowski D, Chute DF, Gustafson J, Chung RT, Williams WW, Elias N. Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation. Artif Organs 2019;43:913-20. [PMID: 31001828 DOI: 10.1111/aor.13473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Alghamdi W, Lotfy K, Weernink C, Alsolami E, Jevnikar A, Luke P, Skaro A, Qumosani K, Brahmania M, Marotta P, Hosseini-moghaddam SM, Teriaky A. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02107-1] [Reference Citation Analysis]
73 Franco A, Balibrea N, Gimeno A, Merino E, Lopez MI, Santiago C, Perez Contreras F. Transplantation of hepatitis C infected kidneys into uninfected recipients. Why not? Nefrologia (Engl Ed) 2018;38:672-3. [PMID: 30006233 DOI: 10.1016/j.nefro.2018.04.005] [Reference Citation Analysis]
74 Vanichanan J, Udomkarnjananun S, Avihingsanon Y, Jutivorakool K. Common viral infections in kidney transplant recipients. Kidney Res Clin Pract 2018;37:323-37. [PMID: 30619688 DOI: 10.23876/j.krcp.18.0063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
75 Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. Pharmaceutics 2021;13:496. [PMID: 33917382 DOI: 10.3390/pharmaceutics13040496] [Reference Citation Analysis]
76 Lee GS, Anesi JA, Besharatian BD, Bittermann T, Hamel S, Goldberg DS. Con: Use of Hepatitis C Virus-Positive Donors Should Be Restricted to Research Protocols. Clin Liver Dis (Hoboken) 2018;12:105-8. [PMID: 30988923 DOI: 10.1002/cld.744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Li AA, Cholankeril G, Cheng XS, Tan JC, Kim D, Toll AE, Nair S, Ahmed A. Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era. Diseases 2018;6:E62. [PMID: 29996536 DOI: 10.3390/diseases6030062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
78 Edmonds C, Carver A, DeClercq J, Choi L, Peter M, Schlendorf K, Perri R, Forbes RC, Concepcion BP. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. Am J Surg 2021:S0002-9610(21)00528-6. [PMID: 34548142 DOI: 10.1016/j.amjsurg.2021.09.005] [Reference Citation Analysis]
79 Cox A, Sulkowski M, Sugarman J. Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. Clin Infect Dis 2020;71:2986-90. [PMID: 32442262 DOI: 10.1093/cid/ciaa640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Nam H, Nilles KM, Levitsky J, Ison MG. Donor-derived Viral Infections in Liver Transplantation. Transplantation 2018;102:1824-36. [PMID: 29979345 DOI: 10.1097/TP.0000000000002326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
81 Cholankeril G, Li AA, Dennis BB, Toll AE, Kim D, Bonham CA, Nair S, Ahmed A. Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients. Clin Gastroenterol Hepatol 2019;17:1634-6. [PMID: 30268562 DOI: 10.1016/j.cgh.2018.09.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]